Aripiprazole (Abilify) is the first partial dopamine agonist to be introduced in England for the treatment of schizophrenia. The emergence of partial dopamine agonists supports the case for the dopamine hypothesis of schizophrenia. Aripiprazole has promising efficacy and is well tolerated. According to the authors, this drug may play a significant role in the future management of patients with schizophrenia.